Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
“Even though the tests have been around for a while, we don’t know how useful they’re really going to be in the clinical setting."
The 30% improvement in survival has brought a Phase III trial to an early halt.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
The new credit card-size rapid antigen test can return results in 15 minutes.
More than 80% of clinical trial participants experienced complete or partial remission.
Guardant360 identifies patients with EGFR mutations, which could guide treatment decisions.
The antibody-drug-conjugate produced an overall response rate of 31%.
More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.
Tecartus led to durable remission in a majority of participants in a Phase II study.
The combination improved both overall survival and patient-reported outcomes.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
The American Cancer Society now calls for vaccination of girls and boys starting at age 9.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.